Home / Companies / Aerovate Therapeutics, Inc. / 16 Apr 2025
Aerovate Therapeutics, Inc.: meeting of 16 Apr 2025
Votes reported on Form N-PX, item by item
39 Form N-PX filers reported votes at the Aerovate Therapeutics, Inc. meeting of 16 Apr 2025. Their records fall into 6 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 50.0% of reported votes for; 38 filers withheld from or voted against at least one nominee.
192 vote records from 39 filers. 21 of the 38 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
64 vote records from 39 filers. 0 of the 38 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
EXTRAORDINARY TRANSACTIONSIssuer
EXTRAORDINARY TRANSACTIONS: management items
Management items in this category are shown together; filers word and number them differently.
119 vote records from 36 filers. 0 of the 35 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
137 vote records from 39 filers. 0 of the 38 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
125 vote records from 39 filers. 11 of the 38 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
67 vote records from 39 filers. 7 of the 38 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Auditor |
|---|---|---|
| Vanguard | For | For |
| BlackRock and iShares | For | For |
| Fidelity | For | For |
| State Street and SPDR | For | For |
| Equitable | Abstain or withhold * | For |
| Charles Schwab | Abstain or withhold * | For |
| Nuveen and TIAA | Abstain or withhold * | For |
| ProShares and ProFunds | Abstain or withhold * | For |
| John Hancock and Manulife | Abstain or withhold * | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | For |
| Goldman Sachs | Abstain or withhold * | For |
| Northern Trust and FlexShares | Abstain or withhold * | For |
| SEI | Abstain or withhold * | For |
| T. Rowe Price | For | For |
| Lincoln Financial | For | For |
| Nationwide | For | For |
| Guggenheim and Rydex | Abstain or withhold * | For |
| Columbia Threadneedle | Abstain or withhold * | For |
| Pacific Life funds | For | For |
| Global X | Abstain or withhold * | For |
| DWS | Abstain or withhold * | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Aerovate Therapeutics, Inc. meeting?
39 Form N-PX filers reported votes at the meeting of 16 Apr 2025. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Aerovate Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Aerovate Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Aerovate Therapeutics, Inc. with a meeting date within three days of 16 Apr 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.